Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit

NORCROSS, Ga., Nov. 18, 2019 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Eliezer Zomer, Ph.D., Vice President, Discovery Research and Product Development for Galectin Therapeutics, will be presenting at the 3rd Annual Anti-Fibrotic Drug Development (AFDD) Summit, held from Nov 18 – 20, 2019 at Revere Hotel Boston Common in Boston, Massachusetts. Dr. Zomer will present Galectin’s discovery program of its next generation of galectin-3 inhibitors for treating chronic fibrotic diseases as well as other diseases. This work is largely that of Galectin Therapeutics’ majority-owned subsidiary Galectin Sciences, LLC in partnership with SBH Sciences of Natick, Massachusetts.
Title: Therapeutics for Chronic Fibrotic Diseases
Date: Tuesday, November 19
Time: 12:35 pmDr. Zomer will also participate on a Q&A Panel: Novel Targets, Molecules and Pathways, also held on Tuesday, at 3:15 pm.Bringing together leading researchers from drug development, the AFDD Summit was established to benchmark candidate success, comprehensively review what is known about fibrotic disease etiology, and challenge the poor preclinical predictability currently limiting translation of anti-fibrotic efficacy.About Galectin TherapeuticsGalectin Therapeutics is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance and use words such as “may,” “estimate,” “could,” “expect” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin (GR-MD-02) will lead to the first therapy for the treatment of fatty liver disease with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and those related to newly discovered classes of small molecule inhibitors and future therapeutic uses of Galectin Sciences LLC. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin; manufacturing of drug product now in scale-up may not be successful or meet regulatory expectations, the Company’s Phase 3 clinical trial for the treatment of fatty liver disease, now in the planning stages, and any future clinical studies, including those in connection with cancer immunotherapy may not proceed and may not produce positive results in a timely fashion, if at all, and could prove time-consuming and costly; plans regarding development, approval, and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.Investor Contact:
Galectin Therapeutics, Inc.
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.comMedia Contact:
Gregory FCA
Rachel Giltz, Senior Account Executive
(215) 297-3607
rachel@gregoryfca.com